Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 15, 2020 - Issue 9
Submit an article Journal homepage
389
Views
5
CrossRef citations to date
0
Altmetric
Drug Discovery Case History

The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease

Miren Ettchetoa Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain;b Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain;c Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain;d Institute of Neuroscience, University of Barcelona, Barcelona, SpainView further author information
,
Oriol Busquetsa Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain;b Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain;c Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain;d Institute of Neuroscience, University of Barcelona, Barcelona, SpainView further author information
,
Elena Sánchez-Lopezd Institute of Neuroscience, University of Barcelona, Barcelona, Spain;e Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain;f Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, SpainView further author information
,
Amanda Canod Institute of Neuroscience, University of Barcelona, Barcelona, Spain;e Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain;f Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, SpainView further author information
,
Patricia R. Manzinea Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain;c Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain;d Institute of Neuroscience, University of Barcelona, Barcelona, Spain;g Department of Gerontology, Federal University of São Carlos (Ufscar), São Carlos, BrazilView further author information
,
Ester Verdaguerc Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain;d Institute of Neuroscience, University of Barcelona, Barcelona, Spain;h Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, SpainView further author information
,
Jordi Olloquequii Laboratory of Cellular and Molecular Pathology, Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, ChileView further author information
,
Carme Auladellc Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain;d Institute of Neuroscience, University of Barcelona, Barcelona, Spain;h Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, SpainView further author information
,
Jaume Folchb Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain;c Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, SpainView further author information
&
Antoni Caminsa Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain;c Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain;d Institute of Neuroscience, University of Barcelona, Barcelona, Spain;i Laboratory of Cellular and Molecular Pathology, Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, ChileCorrespondence[email protected]
View further author information
 show all
Pages 993-1003 | Received 13 Dec 2019, Accepted 07 May 2020, Published online: 26 May 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Francesco Melfi, Simone Carradori, Andrea Angeli & Ilaria D’Agostino. (2023) Nature as a source and inspiration for human monoamine oxidase B (hMAO-B) inhibition: A review of the recent advances in chemical modification of natural compounds. Expert Opinion on Drug Discovery 18:8, pages 851-879.
Read now

Articles from other publishers (4)

K. Poonkuzhali, R. Seenivasagan, J. Prabhakaran & A. Karthika. (2023) Synthesis and Characterization of Chemical engineered PLGA nanosphere: Triggering Mechanism of Catechol-O-methyltransferase Inhibition on in vivo neurodegeneration. Bioorganic Chemistry, pages 106673.
Crossref
Dag Nyholm & Wolfgang H. Jost. (2022) Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Therapeutic Advances in Neurological Disorders 15, pages 175628642211080.
Crossref
Javed Ahmad, Nafis Haider, Mohammad Ahmed Khan, Shadab Md, Nabil A. Alhakamy, Mohammed M. Ghoneim, Sultan Alshehri, Syed Sarim Imam, Mohammad Zaki Ahmad & Awanish Mishra. (2022) Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery. Biochemical Pharmacology 195, pages 114849.
Crossref
Clémence Leung, Olivier Rascol & Margherita Fabbri. (2021) Opicapone for Parkinson’s disease: clinical evidence and future perspectives. Neurodegenerative Disease Management 11:3, pages 193-206.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.